Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
Marcus Today does Technical Scans every day, and on 15 September 2023, they turned up four big stocks (five if you include Resmed CDI (ASX: RMD), seven including resources) that are interestingly oversold on weekly charts.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.67% to 7230.40.
The Ramsay Health Care Ltd (ASX:RHC) share price went up today following the company’s announcement that it was making progress on the sale of its Asian business.
Ultimately, these events shifted the outlooks for overall demand and supply, in turn having impacts on the three drivers of equity market returns: the profit outlook, interest rate outlook and risk premiums.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.20% to 7206.90.
Balaji Gopal is the Head of Adviser Services at Vanguard Australia and one of the key people of the Vanguard organisation here in Australia.
The Resmed CDI (ASX: RMD) share price was crushed after its Q4 2023 financial results. Is Resmed’s share price an allergic reaction to Ozempic, or something else?
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
The Resmed CDI (ASX: RMD) share price is down over 30% over the past 12 months as analysts and investors weigh up the long-term impact of GLP-1 treatments on RMD’s obstructive sleep apnea (OSA) market.
Marcus Today does Technical Scans every day, and on 15 September 2023, they turned up four big stocks (five if you include Resmed CDI (ASX: RMD), seven including resources) that are interestingly oversold on weekly charts.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.67% to 7230.40.
The Ramsay Health Care Ltd (ASX:RHC) share price went up today following the company’s announcement that it was making progress on the sale of its Asian business.
Ultimately, these events shifted the outlooks for overall demand and supply, in turn having impacts on the three drivers of equity market returns: the profit outlook, interest rate outlook and risk premiums.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.20% to 7206.90.
Balaji Gopal is the Head of Adviser Services at Vanguard Australia and one of the key people of the Vanguard organisation here in Australia.
The Resmed CDI (ASX: RMD) share price was crushed after its Q4 2023 financial results. Is Resmed’s share price an allergic reaction to Ozempic, or something else?
Want to level-up your analytical skills and investing insights but don’t know where to start? We can help. Join 40,000+ Australian investors on our mailing list today and we’ll send you our favourite podcasts, courses, resources, investment articles and podcasts every week. Delivered to your inbox every Sunday morning. Grab a coffee and let Owen and the team bring you the best investment insights every week.
